ABLYNX NV
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$455,328
Doctors Paid
11
Transactions
144
2021 Total
$43,931
Payment Breakdown by Category
Research$420,566 (92.4%)
Consulting$28,689 (6.3%)
Travel$2,747 (0.6%)
Food & Beverage$963.62 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $420,566 | 107 | 92.4% |
| Consulting Fee | $28,689 | 15 | 6.3% |
| Travel and Lodging | $2,747 | 11 | 0.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,362 | 1 | 0.5% |
| Food and Beverage | $963.62 | 10 | 0.2% |
Payments by Type
Research
$420,566
107 transactions
General
$34,763
37 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES) | $198,979 | 0 | 67 |
| A randomized, double-blind, multicenter study to evaluate the efficacy and safety of ALX-0171 versus placebo, in addition to standard of care, in adults who have undergone hematopoietic stem cell tran | $92,458 | 0 | 7 |
| A Phase II Multi-center, Randomized, Double-Blind, Placebo-Controlled, Dose-Range Finding Study to Evaluate the Safety and Efficacy of ALX-0061 Administered Subcutaneously in Systemic Lupus Erythemato | $84,944 | 1 | 31 |
| A Randomized, Double-blind, Placebo-controlled, Multicenter Dose Ranging Study of ALX-0171 in Infants and Young Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection | $8,500 | 0 | 1 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Internal Medicine | $22,020 | 2 | $11,010 |
| Hematology & Oncology | $8,532 | 2 | $4,266 |
| Specialist | $7,588 | 1 | $7,588 |
| Hematology | $6,809 | 2 | $3,405 |
| Clinical Pathology/Laboratory Medicine | $4,632 | 1 | $4,632 |
| Emergency Medicine | $2,000 | 1 | $2,000 |
| Pediatric Hematology-Oncology | $2,000 | 1 | $2,000 |
| Infectious Disease | $1,200 | 1 | $1,200 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2019 |
|---|---|---|---|---|
| Dr. Joshua June, Do, DO | Internal Medicine | Lansing, MI | $20,020 | $0 |
| Joseph Kiss | Specialist | Pittsburgh, PA | $7,588 | $0 |
| Ara Metjian, Md, MD | Hematology & Oncology | Aurora, CO | $4,674 | $0 |
| Dr. Xinglong Zheng, M.d., Ph.d, M.D., PH.D | Clinical Pathology/Laboratory Medicine | Kansas City, KS | $4,632 | $0 |
| John Owen, Md, MD | Hematology | Winston Salem, NC | $4,532 | $0 |
| Spero Cataland, M.d, M.D | Hematology & Oncology | Columbus, OH | $3,859 | $0 |
| Dr. Chuanyi Lu, M.d, M.D | Hematology | San Francisco, CA | $2,278 | $0 |
| Dr. Shruti Chaturvedi, M.d, M.D | Internal Medicine | Baltimore, MD | $2,000 | $0 |
| Dr. Guy Young, M.d, M.D | Pediatric Hematology-Oncology | Bozeman, MT | $2,000 | $0 |
| Dr. Bradley Lewis, M.d, M.D | Emergency Medicine | Draper, UT | $2,000 | $0 |
| Roy Chemaly, M.d, M.D | Infectious Disease | Houston, TX | $1,200 | $0 |
About ABLYNX NV
ABLYNX NV has made $455,328 in payments to 11 healthcare providers, recorded across 144 transactions in the CMS Open Payments database. In 2021, the company paid $43,931. The top product by payment volume is CABLIVI ($188,610).
Payments were distributed across 8 medical specialties. The top specialty by payment amount is Internal Medicine ($22,020 to 2 doctors).
Payment categories include: Food & Beverage ($963.62), Consulting ($28,689), Research ($420,566), Travel & Lodging ($2,747).
ABLYNX NV is associated with 1 products in the CMS Open Payments database.